Breast Cancer Research and Treatment

, Volume 129, Issue 1, pp 107–116 | Cite as

Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial

  • Antonella L. Rastelli
  • Marie E. Taylor
  • Feng Gao
  • Reina Armamento-Villareal
  • Shohreh Jamalabadi-Majidi
  • Nicola Napoli
  • Matthew J. Ellis
Clinical trial

Abstract

A double-blind placebo-controlled randomized phase II trial was performed to determine whether High Dose Vitamin D2 supplementation (HDD) in women receiving adjuvant anastrozole improves aromatase inhibitor-induced musculoskeletal symptoms (AIMSS) and bone loss. Patients with early breast cancer and AIMSS were stratified according to their baseline 25-hydroxy vitamin D (25OHD) level. Stratum A (20–29 ng/ml) received either HDD 50,000 IU capsules weekly for 8 weeks then monthly for 4 months or placebo. Stratum B (10–19 ng/ml) received either HDD for 16 weeks and then monthly for 2 months, or placebo. AIMSS was assessed by the Brief Pain Inventory-Short Form (BPI-SF), the Fibromyalgia Impact Questionnaire (FIQ), and the Health Assessment Questionnaire-Disability Index (HAQ-DI) at baseline, 2, 4, and 6 months. Bone Mineral Density (BMD) was measured at baseline and at 6 months. The primary endpoint of the study was the change-from-baseline musculoskeletal pain. The secondary endpoint was the percent change in BMD at 6 months. Sixty women were enrolled. Baseline characteristics were comparable between the groups. At 2 months, FIQ pain (P = 0.0045), BPI worst-pain (P = 0.04), BPI average-pain (P = 0.0067), BPI pain-severity (P = 0.04), and BPI interference (P = 0.034) scores were better in the HDD than placebo group. The positive effect of HDD on AIMSS was stronger across all time points in Stratum B than Stratum A (FIQ pain, P = 0.04; BPI average, P = 0.03; BPI severity, P = 0.03; BPI interference, P = 0.04). BMD at the femoral neck decreased in the placebo and did not change in the HDD group (P = 0.06). Weekly HDD improves AIMSS and may have a positive effect on bone health. Vitamin D supplementation strategies for breast cancer patients on AI should be further investigated.

Keywords

Breast cancer Vitamin D Aromatase-inhibitors Anastrozole, arthralgias Bone mineral density Vitamin D deficiency 

References

  1. 1.
    Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS (2005) Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365(9453):60–62. doi:10.1016/S0140-6736(04)17666-6 PubMedCrossRefGoogle Scholar
  2. 2.
    Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, van de Velde C (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350(11):1081–1092. doi:10.1056/NEJMoa040331350/11/1081 PubMedCrossRefGoogle Scholar
  3. 3.
    Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349(19):1793–1802. doi:10.1056/NEJMoa032312NEJMoa032312 PubMedCrossRefGoogle Scholar
  4. 4.
    Burstein HJ (2007) Aromatase inhibitor-associated arthralgia syndrome. Breast 16(3):223–234. doi:10.1016/j.breast.2007.01.011 PubMedCrossRefGoogle Scholar
  5. 5.
    Winters L, Habin K, Flanagan J, Cashavelly BJ (2010) “I feel like I am 100 years old!” managing arthralgias from aromatase inhibitors. Clin J Oncol Nurs 14(3):379–382. doi:10.1188/10.CJON.379-382 PubMedCrossRefGoogle Scholar
  6. 6.
    Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369(9561):559–570. doi:10.1016/S0140-6736(07)60200-1 PubMedCrossRefGoogle Scholar
  7. 7.
    Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in combination) trial efficacy and safety update analyses. Cancer 98(9):1802–1810. doi:10.1002/cncr.11745 PubMedCrossRefGoogle Scholar
  8. 8.
    Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25(25):3877–3883. doi:10.1200/JCO.2007.10.7573 PubMedCrossRefGoogle Scholar
  9. 9.
    Partridge AH, La Fountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26(4):556–562. doi:10.1200/JCO.2007.11.5451 PubMedCrossRefGoogle Scholar
  10. 10.
    Fontaine C, Meulemans A, Huizing M, Collen C, Kaufman L, De Mey J, Bourgain C, Verfaillie G, Lamote J, Sacre R, Schallier D, Neyns B, Vermorken J, De Greve J (2008) Tolerance of adjuvant letrozole outside of clinical trials. Breast 17(4):376–381. doi:10.1016/j.breast.2008.02.006 PubMedCrossRefGoogle Scholar
  11. 11.
    Cuzick J, Sestak I, Cella D, Fallowfield L (2008) Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 9(12):1143–1148. doi:10.1016/S1470-2045(08)70259-6 PubMedCrossRefGoogle Scholar
  12. 12.
    Crew KD, Shane E, Cremers S, McMahon DJ, Irani D, Hershman DL (2009) High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol 27(13):2151–2156. doi:10.1200/JCO.2008.19.6162 PubMedCrossRefGoogle Scholar
  13. 13.
    Holick MF (2007) Vitamin D deficiency. N Engl J Med 357(3):266–281. doi:10.1056/NEJMra070553 PubMedCrossRefGoogle Scholar
  14. 14.
    Waltman NL, Ott CD, Twiss JJ, Gross GJ, Lindsey AM (2009) Vitamin D insufficiency and musculoskeletal symptoms in breast cancer survivors on aromatase inhibitor therapy. Cancer Nurs 32(2):143–150. doi:10.1097/01.NCC.0000339262.44560.92 PubMedCrossRefGoogle Scholar
  15. 15.
    Taylor M, Rastelli, A, Civitelli, R et al (2004) Incidence of 25-OH vitamin D deficiency in patients with a history of breast cancer who have musculoskeletal symptomatology. In: San Antonio breast cancer symposium, vol 88. Breast Cancer Research and Treatment Journal, San AntonioGoogle Scholar
  16. 16.
    Khan QJ, Reddy PS, Kimler BF, Sharma P, Baxa SE, O’Dea AP, Klemp JR, Fabian CJ (2010) Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 119(1):111–118. doi:10.1007/s10549-009-0495-x PubMedCrossRefGoogle Scholar
  17. 17.
    Prieto-Alhambra D, Javaid MK, Servitja S, Arden NK, Martinez-Garcia M, Diez-Perez A, Albanell J, Tusquets I, Nogues X (2011) Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Res Treat 125(3):869–878. doi:10.1007/s10549-010-1075-9 PubMedCrossRefGoogle Scholar
  18. 18.
    Bringhurst FR DM, Kronenberg HM (2008) Disorders of mineral metabolism. In: Kronenberg HM SM, Polansky KS, Larsen PR (eds) Williams textbook of endocrinology. WB Saunders, PhiladelphiaGoogle Scholar
  19. 19.
    Wysolmerski JJ IK (2008) The parathyroid glands, hypercalcemia, and hypocalcemia. In: Kronenberg HM, Melmed S, Polansky KS, Larsen PR (eds) Williams textbook of endocrinology. WB Saunders, PhiladelphiaGoogle Scholar
  20. 20.
    Chapuy MC, Pamphile R, Paris E, Kempf C, Schlichting M, Arnaud S, Garnero P, Meunier PJ (2002) Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int 13(3):257–264PubMedCrossRefGoogle Scholar
  21. 21.
    Sahota O, Mundey MK, San P, Godber IM, Lawson N, Hosking DJ (2004) The relationship between vitamin D and parathyroid hormone: calcium homeostasis, bone turnover, and bone mineral density in postmenopausal women with established osteoporosis. Bone 35(1):312–319. doi:10.1016/j.bone.2004.02.003S8756328204000675 PubMedCrossRefGoogle Scholar
  22. 22.
    Ooms ME, Roos JC, Bezemer PD, van der Vijgh WJ, Bouter LM, Lips P (1995) Prevention of bone loss by vitamin D supplementation in elderly women: a randomized double-blind trial. J Clin Endocrinol Metab 80(4):1052–1058PubMedCrossRefGoogle Scholar
  23. 23.
    Mann GB, Kang YC, Brand C, Ebeling PR, Miller JA (2009) Secondary causes of low bone mass in patients with breast cancer: a need for greater vigilance. J Clin Oncol 27(22):3605–3610. doi:10.1200/JCO.2008.20.2549 PubMedCrossRefGoogle Scholar
  24. 24.
    Basha B, Rao DS, Han ZH, Parfitt AM (2000) Osteomalacia due to vitamin D depletion: a neglected consequence of intestinal malabsorption. Am J Med 108(4):296–300. doi:10.1016/S0002-9343(99)00460-X PubMedCrossRefGoogle Scholar
  25. 25.
    Bhan A, Rao AD, Rao DS (2010) Osteomalacia as a result of vitamin D deficiency. Endocrinol Metab Clin North Am 39(2):321–331 (table of contents). doi:10.1016/j.ecl.2010.02.001 Google Scholar
  26. 26.
    Plotnikoff GA, Quigley JM (2003) Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. Mayo Clin Proc 78(12):1463–1470PubMedCrossRefGoogle Scholar
  27. 27.
    Holick MF (2007) Optimal vitamin D status for the prevention and treatment of osteoporosis. Drugs Aging 24(12):1017–1029PubMedCrossRefGoogle Scholar
  28. 28.
    Cleeland CS, Ryan KM (1994) Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 23(2):129–138PubMedGoogle Scholar
  29. 29.
    Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, Cleeland C, Dionne R, Farrar JT, Galer BS, Hewitt DJ, Jadad AR, Katz NP, Kramer LD, Manning DC, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robinson JP, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Witter J (2003) Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain 106(3):337–345PubMedCrossRefGoogle Scholar
  30. 30.
    Burckhardt CS, Clark SR, Bennett RM (1991) The fibromyalgia impact questionnaire: development and validation. J Rheumatol 18(5):728–733PubMedGoogle Scholar
  31. 31.
    Bennett R (2005) The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin Exp Rheumatol 23(5 suppl 39):S154–S162PubMedGoogle Scholar
  32. 32.
    Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23(2):137–145PubMedCrossRefGoogle Scholar
  33. 33.
    Armas LA, Hollis BW, Heaney RP (2004) Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 89(11):5387–5391. doi:10.1210/jc.2004-0360 PubMedCrossRefGoogle Scholar
  34. 34.
    Bell NH, Epstein S, Greene A, Shary J, Oexmann MJ, Shaw S (1985) Evidence for alteration of the vitamin D-endocrine system in obese subjects. J Clin Invest 76(1):370–373. doi:10.1172/JCI111971 PubMedCrossRefGoogle Scholar
  35. 35.
    Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF (2000) Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 72(3):690–693PubMedGoogle Scholar
  36. 36.
    Heaney RP, Recker RR, Grote J, Horst RL, Armas LA (2011) Vitamin D(3) is more potent than vitamin D(2) in humans. J Clin Endocrinol Metab 96(3):E447–E452. doi:10.1210/jc.2010-2230 PubMedCrossRefGoogle Scholar
  37. 37.
    Buchanan JR, Santen R, Cauffman S, Cavaliere A, Greer RB, Demers LM (1986) The effect of endogenous estrogen fluctuation on metabolism of 25-hydroxyvitamin D. Calcif Tissue Int 39(3):139–144PubMedCrossRefGoogle Scholar
  38. 38.
    Arora A, Potter JF (2004) Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer. J Am Geriatr Soc 52(4):611–616. doi:10.1111/j.1532-5415.2004.52171.xJGS52171 PubMedCrossRefGoogle Scholar
  39. 39.
    Drocourt L, Ourlin JC, Pascussi JM, Maurel P, Vilarem MJ (2002) Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J Biol Chem 277(28):25125–25132. doi:10.1074/jbc.M201323200M201323200 PubMedCrossRefGoogle Scholar
  40. 40.
    Holick MF (2008) Vitamin D: a D-lightful health perspective. Nutr Rev 66(10 suppl 2):S182–S194. doi:10.1111/j.1753-4887.2008.00104.x PubMedCrossRefGoogle Scholar
  41. 41.
    Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, Barlow D, Makris A, Eastell R (2010) Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 28(6):967–975. doi:10.1200/JCO.2009.24.5902 PubMedCrossRefGoogle Scholar
  42. 42.
    Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HC, Jin L, Warsi GM, Ericson SG, Perez EA (2009) Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 9(2):77–85. doi:10.3816/CBC.2009.n.015 PubMedCrossRefGoogle Scholar
  43. 43.
    Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann MW, Clack G (2008) Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 26(7):1051–1057. doi:10.1200/JCO.2007.11.0726 PubMedCrossRefGoogle Scholar
  44. 44.
    Markopoulos C, Tzoracoleftherakis E, Polychronis A, Venizelos B, Dafni U, Xepapadakis G, Papadiamantis J, Zobolas V, Misitzis J, Kalogerakos K, Sarantopoulou A, Siasos N, Koukouras D, Antonopoulou Z, Lazarou S, Gogas H (2010) Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Breast Cancer Res 12(2):R24. doi:10.1186/bcr2565 PubMedCrossRefGoogle Scholar
  45. 45.
    Lester JE, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Hannon RA, Coleman RE (2008) Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 14(19):6336–6342. doi:10.1158/1078-0432.CCR-07-5101 PubMedCrossRefGoogle Scholar
  46. 46.
    Lonning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Paolini J, Polli A, Massimini G (2005) Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23(22):5126–5137. doi:10.1200/JCO.2005.07.097 PubMedCrossRefGoogle Scholar
  47. 47.
    Punnonen R, Salmi J, Tuimala R, Jarvinen M, Pystynen P (1986) Vitamin D deficiency in women with femoral neck fracture. Maturitas 8(4):291–295PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • Antonella L. Rastelli
    • 1
  • Marie E. Taylor
    • 2
  • Feng Gao
    • 3
  • Reina Armamento-Villareal
    • 4
  • Shohreh Jamalabadi-Majidi
    • 1
  • Nicola Napoli
    • 4
  • Matthew J. Ellis
    • 1
  1. 1.Department of Medicine, Division of OncologyWashington University School of MedicineSt. LouisUSA
  2. 2.Department of Radiation OncologyWashington University School of MedicineSt. LouisUSA
  3. 3.Division of BiostatisticsWashington University School of MedicineSt. LouisUSA
  4. 4.Department of Medicine, Division of Bone and Mineral DiseasesWashington University School of MedicineSt. LouisUSA

Personalised recommendations